Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 7;8(2):e000973. doi: 10.1136/jitc-2020-000973

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Mechanism study of Amuc in inducing antitumor-specific immune responses. (A–C) The involvement of immune responses in the tumor-infiltrating lymphocytes treated with Amuc. (A) 3D-principal coordinate analysis (3D-PCoA) analysis of the gene expression profiles. (B) Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of the identified differentially expressed genes. (C) Gene ontology (GO) enrichment analysis of the identified differentially expressed genes involved in the immune functions. (D–G) The involvement of TLR2 pathway in the antitumor effects of Amuc in tumor-bearing mice, BLP acts as a TLR1/TLR2 agonist while CU-CPT22 acts as a TLR1/TLR2 antagonist. (D) Tumor growth under different treatment in CT26 tumor-bearing mice (n=6). (E) The proportions of IFN-γ⁺ CD8⁺ in CD3⁺ T cells in tumor-draining lymph nodes. (F) The proportions of Foxp3⁺ CD25⁺ in CD4⁺ T cells in tumor-draining lymph nodes. (G) The proportions of CD11c⁺ MHC-II⁺ cells in tumor-draining lymph nodes. All data are shown as mean±SD (*p<0.05, **p<0.01). BLP, bacterial lipoprotein; ECM, extracellular matrix; FDR, false discovery rate; IFN, interferon; MHC, major histocompatibility complex; NF-κB, nuclear factor-κB; PBS, phosphate-buffered saline; TLR2, toll-like receptor 2.